Results 71 to 80 of about 6,610 (157)

Budget impact and cost-utility analysis of prophylactic emicizumab versus on-demand bypassing agents for adolescent severe haemophilia A patients with inhibitors in India

Heliyon
Introduction: Severe Haemophilia A patients with inhibitors are currently being treated with bypassing agents like activated prothrombin complex concentrates (aPCC) and recombinant factor VIIa.
Yuvaraj Krishnamoorthy, Dhanajayan Govindan, Narasimhapriyan Kannan, Marie Gilbert Majella, Vishnu Shankar Hariharan, Vivek Valliappan   +5 more
doaj   +1 more source

Off-label use of recombinant factor VIIa for neonatal pulmonary hemorrhage; a single-center experience

The Turkish Journal of Pediatrics
Background. Pulmonary hemorrhage (PH) leads to acute and catastrophic deterioration in neonates, and there is no curative treatment available. Off-label use of recombinant Factor VIIa (rFVIIa) is a promising treatment to control bleeding.
Özge Serçe Pehlevan, Ayna Atayeva, Ayla Günlemez, Sibel Balcı   +3 more
doaj   +1 more source

Thrombosis and recombinant factor VIIa [PDF]

Journal of Thrombosis and Haemostasis, 2004
openaire   +2 more sources

Glanzmann’s thrombasthenia: A nightmare for hernia surgeons

Journal of Minimal Access Surgery
Glanzmann’s thrombasthenia is a rare inherited disorder affecting one in one million. It is characterised by a lack of platelet aggregation due to a defect in the platelet membrane receptor complex (αIIb/βIIIa), which mediates the aggregation of ...
Jignesh Gandhi, Aarsh Gajjar, Pravin Shinde, Yogesh Takalkar   +3 more
doaj   +1 more source

Plenary Abstracts Session & Oral Presentations

HemaSphere, Volume 10, Issue S1, June 2026.
wiley   +1 more source

Successful Desensitization Protocol in an Infant Following Anaphylaxis Secondary to Recombinant Factor VIIa. [PDF]

Pediatr Allergy Immunol Pulmonol, 2020
Ulusoy Severcan E, Cigerci Gunaydin N, Hekimci Ozdemir H, Gulen F, Kavakli K, Tanac R, Demir E.   +6 more
europepmc   +1 more source

Therapeutic doses of recombinant factor VIIa in hemophilia generates thrombin in platelet-dependent and -independent mechanisms. [PDF]

J Thromb Haemost, 2020
Keshava S, Pendurthi UR, Esmon CT, Rao LVM.   +3 more
europepmc   +1 more source

Use of Low-Dose Recombinant Factor Ⅶa for Uncontrolled Perioperative Bleeding. [PDF]

Dose Response, 2020
Chang ZG, Chu X, Chen W, Hu JH, Gong JW, Liu DD, He Q, Feng Z, Xiao SR, Liu YL.   +9 more
europepmc   +1 more source

Antithrombotic and hemostatic stewardship: evaluation of clinical outcomes and adverse events of recombinant factor VIIa (Novoseven^®) utilization at a large academic medical center. [PDF]

Ther Adv Cardiovasc Dis, 2020
Marsh K, Green D, Raco V, Papadopoulos J, Ahuja T.   +4 more
europepmc   +1 more source

Critical appraisal of the role of recombinant activated factor VII in the treatment of hemophilia patients with inhibitors

Journal of Blood Medicine, 2010
Ampaiwan Chuansumrit1, Pantep Angchaisuksiri2, Nongnuch Sirachainan11Departments of Pediatrics and 2Medicine, Faculty of Medicine, Ramathibodi Hospital, Mahidol University,  Bangkok, ThailandAbstract: Hemophilia patients with inhibitors faced ...
Ampaiwan Chuansumrit, Pantep Angchaisuksiri, Nongnuch Sirachainan   +2 more
doaj